Physician profile
Rachel Smith
NPI 1366091209
$1,558.15
in general payments reported to CMS, 2019-2025
21 companies · $734 in 2025
The $734 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.56 · 2023: $255 · 2024: $528 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $204.10 | 2023-2025 | Winrevair, Keytruda, Recarbrio |
| Grifols USA, LLC | $168.01 | 2023-2025 | Prolastin-C Liquid |
| Boston Scientific Corporation | $166.28 | 2025 | General - Therapies |
| Atricure, INC. | $136.20 | 2024 | |
| United Therapeutics Corporation | $123.99 | 2023-2025 | Tyvaso, Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.96 | 2024 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $84.23 | 2023-2025 | Dupixent |
| Genzyme Corporation | $78.20 | 2023-2024 | |
| Verona Pharma, INC. | $77.95 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.51 | 2023-2025 | Ofev |
| Glaxosmithkline, LLC. | $54.18 | 2024 | Trelegy Ellipta, Arexvy |
| Electromed, INC. | $54.17 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $44.76 | 2025 | Yupelri |
| Mylan Specialty L.P. | $39.86 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $33.81 | 2022-2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.09 | 2025 | Ninlaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.52 | 2023 | Fasenra |
| Lilly USA, LLC | $21.77 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $15.52 | 2023 | |
| Zimmer Biomet Holdings, INC. | $13.50 | 2024 | Sternalock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.